The size of the European HIV Therapeutics Market was worth USD 6.19 billion in 2022 and estimated to be growing at a CAGR of 1.3%, to reach USD 6.60 billion by 2027.
One of the significant factors catalyzing the market growth is the growing prevalence of HIV/AIDS in Europe. The majority in the age group between 15–49 years ranged from a high of 1.25% in Russia to a low value of 0.15% in other European eleven countries. HIV transmission is becoming a significant public health concern in Europe, affecting more than 2 million people. The European Center for Disease Prevention and Control and the WHO Regional Office for Europe found that while epidemic patterns and trends vary widely across European countries, nearly 137,000 people were diagnosed with HIV in the European region in 2019, of whom 25,000 in the EU/EEA. These growing numbers will drive the market growth rate during the analysis period.
The government is working jointly with international authorities to control and limit the spread of this infection. However, according to WHO, the number of undiagnosed people in the European region is rising. According to data released by ECDC and WHO, more than 136,000 people were diagnosed for the first time in 2019, of which about 20% were diagnosed in the EU and with 80% of them residing in the eastern part of Europe. One in two HIV diagnoses in the late/critical stage of the infection leads to severe complications. In addition, factors such as mother-to-child transmission, errors leading to transfusion of HIV-infected blood, the social stigma associated with HIV, and its prevention measures increase the number of deaths caused by HIV/AIDS.
The widespread availability of antiretroviral therapy (ART) and other drugs to provide symptomatic relief will support the European HIV therapeutics market in the years to come. In addition, the latest drug combinations with lesser adverse effects and successful research and development activities will help the HIV therapeutics market in Europe.
However, a significant challenge persisting in the market is the late detection of the infection, with people often not getting tested or avoiding medication to reduce peer pressure. Moreover, shortages of ART and the limited positive effect of these generic drugs will challenge the European HIV therapeutics market over the forecast period.
This research report on the European HIV therapeutics market has been segmented & sub-segmented into the following categories:
Geographically, North America, trailed by Europe, had the highest market share for HIV therapeutics worldwide in 2020 because of the affordability and availability of costly treatment for HIV infections and developments in medication treatments in this region.
The UK HIV therapeutics market is expected to be the fastest-growing regional market in Europe and will maintain its position during the forecast period. This regional growth can be attributed to various factors like the high prevalence of HIV/AIDS, well-developed health infrastructure, growing awareness camps and screenings, and the presence of favorable reimbursement policies in the region. In 2017, the prevalence rate of HIV in the UK was recorded at 101,600, with 92% of them being diagnosed. The recorded prevalence was highest among gay/bisexual men across London, with around 83 per 1000 gay, and these bisexual men were aged between 15-74. Moreover, the presence of prominent pharmaceutical companies in this region helps the market grow.
The German HIV therapeutics market is likely to be the second-largest market supported by the presence of a large number of people living with HIV/AIDS in this region. Within Germany, the HIV incidence is persistently highest across major cities, with Munich and Cologne being reported as having the highest incidence rates in Germany, with 16.35 and 11.74 per 100,000 2.3 respectively. Currently, the total number of HIV-infected patients is well over 84,700 in Germany.
KEY MARKET PLAYERS:
A few promising companies in the European HIV therapeutics market profiled in this report are GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Merck Hoffmann-La Roche, and Gilead Sciences.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com